Last update 01 Nov 2024

Phenazopyridine Hydrochloride

Last update 01 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryPhenazopyridine, a diminutive molecule, serves primarily as an analgesic agent for urinary tract pain. Its mode of action involves alleviating the discomfort associated with urinary tract infections, bladder inflammation, and other related maladies. The inception of phenazopyridine's use dates back to 1928 and, since then, it has burgeoned into a popular choice for individuals experiencing arduous urination or other urinary tract symptoms. It is crucial to note, however, that while phenazopyridine effectively mitigates pain, it does not remedy the underlying condition that engenders the discomfort. Thus, healthcare professionals must supervise phenazopyridine use as it may interact adversely with other medications and engender potential side effects.

Drug Type

Small molecule drug

Synonyms

2,6-Diamino-3-(phenylazo)pyridine, 2,6-Diamino-3-phenylazopyridine, 3-(Phenylazo)-2,6-pyridinediamine

+ [7]

Target-

Mechanism-

Therapeutic Areas

Nervous System DiseasesInfectious DiseasesOther Diseases

Active Indication

PainShock, Septic

Inactive Indication

BurnsDysuriaUrinary Incontinence+ [1]

Originator Organization-

Active Organization

University of Western OntarioKaren Pharmaceutical Co. Ltd.

Inactive Organization

Pro Doc LtéeAmneal Intermediate, Inc.Laboratórios Osório de Moraes Ltda

Drug Highest PhaseApproved

First Approval Date

US (01 Jan 1928)

Regulation-

Structure

Molecular FormulaC11H12ClN5

InChIKeyQQBPIHBUCMDKFG-UHFFFAOYSA-N

CAS Registry136-40-3

View All Structures (2)

Clinical Trials associated with Phenazopyridine Hydrochloride

NCT06514430 / Not yet recruitingPhase 4IIT

Prophylactic Analgesia in Outpatient Intradetrusor onabotulinumtoxinA Injections: Efficacy and Feasibility of Alternative Pain Control Methods in a Diverse Urban Patient Population

The goal of this clinical trial is to learn more about using phenazopyridine (Pyridium) for pain control during bladder onabotulinumtoxinA ("botox") injections for surgical management of overactive bladder (OAB) for patients at Montefiore Medical Center in The Bronx. It will also learn about if using the phenazopyridine pill affects how satisfied patients are with their experience, how much pain patients feel afterwards, and if doctors think using the Pyridium pill affected how they performed the procedure. The main question it aims to answer is:
- Is oral phenazopyridine at least as good as intravesical lidocaine is for managing pain with bladder botox injections for OAB in Montefiore patients?
Researchers will compare phenazopyridine to intravesical lidocaine, a liquid put into the bladder, to see if phenazopyridine is at least as good at controlling pain with bladder botox injections as intravesical lidocaine is.
Participants will be assigned, by chance, to receive either the oral phenazopyridine pill or the intravesical lidocaine as their pain control for the procedure.

Start Date01 Oct 2024

Sponsor / Collaborator

Montefiore Medical Center

NCT06577493 / Not yet recruitingPhase 4IIT

Effectiveness of Phenazopyridine for Pain Following Urodynamics

The purpose of the study is to determine if taking phenazopyridine (AZO) at the time of urodynamic study testing will decrease pain experienced by patients after undergoing urodynamic testing.

Start Date15 Sep 2024

Sponsor / Collaborator

University of South Florida

CTRI/2024/06/068294 / Not yet recruitingPhase 3

A Randomized Double blinded Placebo controlled study to evaluate the efficacy of Phenazopyridine with Nitrofurantoin in patients with Urinary tract infection - NIL

Start Date15 Jun 2024

Sponsor / Collaborator-

100 Clinical Results associated with Phenazopyridine Hydrochloride

100 Translational Medicine associated with Phenazopyridine Hydrochloride

100 Patents (Medical) associated with Phenazopyridine Hydrochloride

313

Literatures (Medical) associated with Phenazopyridine Hydrochloride

13 Sep 2024·Science Advances

Modeling Lewy body disease with SNCA triplication iPSC-derived cortical organoids and identifying therapeutic drugs

Article

Author: Li, Fuyao ; Carr, Jonathan ; Caulfield, Thomas ; DeTure, Michael ; You, Yang ; Dickson, Dennis W. ; Santhakumar, Hannah ; Bu, Guojun ; Lu, Wenyan ; O’Leary, Justin ; Jin, Yunjung ; Ikezu, Tadafumi C. ; Selvaraj, Manikandan ; Martens, Yuka A. ; Zhao, Na ; Beasley, Alexandra I. ; McLean, Pamela J. ; Li, Yonghe ; Zhu, Yiyang ; Koga, Shunsuke ; Lolo, Kiara ; Ikezu, Tsuneya ; Li, Zonghua ; Ross, Owen A. ; Kanekiyo, Takahisa ; Wszolek, Zbigniew K. ; Davis, Mary D.

Aggregated α-synuclein (α-SYN) proteins, encoded by the SNCA gene, are hallmarks of Lewy body disease (LBD), affecting multiple brain regions. However, the specific mechanisms underlying α-SYN pathology in cortical neurons, crucial for LBD-associated dementia, remain unclear. Here, we recapitulated α-SYN pathologies in human induced pluripotent stem cells (iPSCs)–derived cortical organoids generated from patients with LBD with SNCA gene triplication. Single-cell RNA sequencing, combined with functional and molecular validation, identified synaptic and mitochondrial dysfunction in excitatory neurons exhibiting high expression of the SNCA gene, aligning with observations in the cortex of autopsy-confirmed LBD human brains. Furthermore, we screened 1280 Food and Drug Administration–approved drugs and identified four candidates (entacapone, tolcapone, phenazopyridine hydrochloride, and zalcitabine) that inhibited α-SYN seeding activity in real-time quaking-induced conversion assays with human brains, reduced α-SYN aggregation, and alleviated mitochondrial dysfunction in SNCA triplication organoids and excitatory neurons. Our findings establish human cortical LBD models and suggest potential therapeutic drugs targeting α-SYN aggregation for LBD.

01 Sep 2024·Chemosphere

Removal of phenazopyridine from water, synthetic urine, and real sample by adsorption using graphene oxide: A DFT theoretical/experimental approach

Article

Author: Silva, Luis Felipe Oliveira ; Foucaud, Yann ; Oliveira, Marcos Leandro Silva ; Bruckmann, Franciele da Silva ; Pinheiro, Raphael Forgearini ; Dotto, Guilherme Luiz ; Badawi, Michael

Herein, graphene oxide was used as the highly efficient phenazopyridine adsorbent from aqueous medium, synthetic, and human urine. The nanoadsorbent was characterized by different instrumental techniques. The adsorption capacity (1253.17 mg g^-1) was reached at pH 5.0, using an adsorbent dosage of 0.125 g L^-1 at 298 K. The Sips and Langmuir described the equilibrium data well. At the same time, the pseudo-second order was more suitable for fitting the kinetic data. Thermodynamic parameters revealed the exothermic nature of adsorption with an increase in randomness at the solid-liquid interface. The magnitude of the enthalpy variation value indicates that the process involves the physisorption phenomenon. At the same time, ab initio molecular dynamics data corroborated with the thermodynamic results, indicating that adsorbent and adsorbate establish hydrogen bonds through the amine groups (adsorbate) and hydroxyl groups on the adsorbent surface (weak interactions). Electrostatic interactions are also involved. Additionally, the adsorption assays conducted in simulated medium and human urine showed the excellent performance of adsorbent material to remove the drug in real concentrations excreted by the kidneys (removal values higher than 60%).

01 Sep 2024·Urology Practice

Cost Analysis of Oral Phenazopyridine vs Intravesical Lidocaine for Preprocedural Analgesia for Intradetrusor OnabotulinumtoxinA Injections

Article

Author: Stewart, Lauren ; Jericevic, Dora ; Siddique, Moiuri ; Wang, Rui ; Kapur, Anjali

INTRODUCTIONOffice administration of intradetrusor onabotulinumtoxinA is commonly used to treat overactive bladder. For preprocedure analgesia, either 50 mL 2% intravesical lidocaine instillation for 20 to 30 minutes or 200 mg oral phenazopyridine can be used. Phenazopyridine is associated with shorter appointment times and is noninferior to lidocaine for pain control in this setting. We performed a cost analysis of phenazopyridine vs lidocaine for analgesia before office intradetrusor onabotulinumtoxinA injection for the treatment of idiopathic overactive bladder.METHODSA health care sector-perspective cost analysis was performed. The following assumptions were made: (1) similar efficacy of each medication in providing adequate analgesia, (2) similar physician ease of performing the procedure with either analgesic, and (3) similar patient satisfaction with either analgesic. Average cost of medications, adverse reactions, nursing tasks, and office visit time were found in publicly available data. Sensitivity analyses were performed using TreeAge Pro 2021, R1 software.RESULTSPhenazopyridine is less costly compared to lidocaine per visit for office intradetrusor onabotulinumtoxinA injection ($827 vs $925). A difference of $98 per procedure provides a total annual cost savings of over $24 million if all procedures are performed with phenazopyridine instead of lidocaine. Sensitivity analysis showed that phenazopyridine remained less costly under most circumstances, and threshold analysis provided exact circumstances under which phenazopyridine is no longer cost saving.CONCLUSIONSPhenazopyridine provides cost savings compared to lidocaine for analgesia before office intradetrusor onabotulinumtoxinA injection for the treatment of idiopathic overactive bladder. If adopted by providers nationwide, phenazopyridine may reduce health care spending and minimize office visit time while maintaining patient pain control and satisfaction.

News (Medical) associated with Phenazopyridine Hydrochloride

31 Jan 2023

·www.prnewswire.com

Interstitial cystitis (IC) drugs market size to increase by USD 369.58 million: Analysis of major players as well as the key contributor region - Technavio

North America will account for 35% of the global interstitial cystitis (IC) drugs market NEW YORK, Jan. 30, 2023 /PRNewswire/ -- North America will account for 35% of the global Interstitial cystitis (IC) drugs market growth. The increasing cases of interstitial cystitis and the rise in research funding are driving the growth of the regional market. The Interstitial Cystitis Drugs Market by Type, Distribution Channel, and Geography - Forecast and Analysis 2023-2027 report has been published by Technavio. Market growth is estimated to accelerate at a CAGR of 5.9% and register an incremental growth of USD 369.58 million during the forecast period. The report provides a comprehensive analysis of growth opportunities at regional levels, new product launches, the latest trends, and the post-pandemic recovery of the global market. Download a PDF Sample Report Continue Reading Technavio has announced its latest market research report titled Global Interstitial Cystitis Drugs Market Company Profiles The interstitial cystitis (IC) drugs market report includes information on the key products and recent developments of leading vendors, including: Amneal Pharmaceuticals Inc: The company offers interstitial cystitis and other related drugs such as Pyridium. Astellas Pharma Inc: The company offers interstitial cystitis drugs such as Rosiptor. Bayer AG: The company offers interstitial cystitis drugs such as Aleve and Aktion. Eli Lilly and Co: The company offers interstitial cystitis and other related drugs such as Tadalafil. Johnson and Johnson: The company offers interstitial cystitis drugs such as Elmiron. Kyorin Pharmaceutical Co. Ltd. Mission Pharmacal Co. Perrigo Co. Plc Pfizer Inc. Purdue Pharma LP Seikagaku Corp. To gain access to more vendor profiles available with Technavio, buy the report! Market Dynamics The market is driven by factors such as the high prevalence of interstitial cystitis, increasing awareness of interstitial cystitis, and increasing grants for research on interstitial cystitis. However, the lack of approved drugs is hindering the market growth. Competitive Analysis The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share, among others. Request a Sample Market Segmentation By type, the market is segmented into oral therapy and intravesical therapy. The oral therapy segment accounted for the largest share of the market. By geography, the market is segmented into North America, Europe, Asia, and Rest of World (ROW). North America held the largest share of the market. Related Reports: Chronic Obstructive Pulmonary Disease Drugs Market by Product, Distribution Channel and Geography - Forecast and Analysis 2023-2027: The chronic obstructive pulmonary disease drugs market is estimated to grow at a CAGR of 6.09% between 2022 and 2027. The size of the market is forecast to increase by USD 6,654.49 million. The rising prevalence of COPD is notably driving the market growth, although factors such as the high cost of conducting clinical trials in COPD may impede the market growth. Allergy Immunotherapies Market by Product, Type, and Geography - Forecast and Analysis 2023-2027: The allergy immunotherapies market is estimated to grow at a CAGR of 8.95% between 2022 and 2027. The size of the market is forecast to increase by USD 1,010.37 million. The increasing prevalence of allergies is notably driving the market growth, although factors such as trial failures may impede the market growth. Technavio's library includes over 17,000+ reports, covering more than 2,000 emerging technologies. Subscribe to our "Basic Plan" at just USD 5,000 and get lifetime access to Technavio Insights What are the key data covered in this interstitial cystitis (IC) drugs market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of interstitial cystitis (IC) drugs market between 2023 and 2027 Precise estimation of the size of interstitial cystitis (IC) drugs market and its contribution to the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of interstitial cystitis (IC) drugs market across North America, Europe, Asia, and Rest of World (ROW) A thorough analysis of the market's competitive landscape and detailed information about vendors Comprehensive analysis of factors that will challenge the growth of interstitial cystitis (IC) drugs market vendors Browse for Technavio "Health Care" Research Reports Table of Content 1 Executive Summary 2 Market Landscape 2.1 Market ecosystem Exhibit 01: Parent market Exhibit 02: Market characteristics 2.2 Value chain analysis Exhibit 03: Value chain analysis: Pharmaceuticals 3 Market Sizing 3.1 Market definition Exhibit 04: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 05: Market segments 3.3 Market size 2020 3.4 Market outlook: Forecast for 2020 - 2025 Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million) Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 08: Five forces analysis 2020 & 2025 4.2 Bargaining power of buyers Exhibit 09: Bargaining power of buyers 4.3 Bargaining power of suppliers Exhibit 10: Bargaining power of suppliers 4.4 Threat of new entrants Exhibit 11: Threat of new entrants 4.5 Threat of substitutes Exhibit 12: Threat of substitutes 4.6 Threat of rivalry Exhibit 13: Threat of rivalry 4.7 Market condition Exhibit 14: Market condition - Five forces 2020 5 Market Segmentation by Type 5.1 Market segments Exhibit 15: Type - Market share 2020-2025 (%) 5.2 Comparison by Type Exhibit 16: Comparison by Type 5.3 Oral therapy - Market size and forecast 2020-2025 Exhibit 17: Oral therapy - Market size and forecast 2020-2025 ($ million) Exhibit 18: Oral therapy - Year-over-year growth 2020-2025 (%) 5.4 Intravesical therapy - Market size and forecast 2020-2025 Exhibit 19: Intravesical therapy - Market size and forecast 2020-2025 ($ million) Exhibit 20: Intravesical therapy - Year-over-year growth 2020-2025 (%) 5.5 Market opportunity by Type Exhibit 21: Market opportunity by Type 6 Customer landscape 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 23: Market share by geography 2020-2025 (%) 7.2 Geographic comparison Exhibit 24: Geographic comparison 7.3 North America - Market size and forecast 2020-2025 Exhibit 25: North America - Market size and forecast 2020-2025 ($ million) Exhibit 26: North America - Year-over-year growth 2020-2025 (%) 7.4 Europe - Market size and forecast 2020-2025 Exhibit 27: Europe - Market size and forecast 2020-2025 ($ million) Exhibit 28: Europe - Year-over-year growth 2020-2025 (%) 7.5 Asia - Market size and forecast 2020-2025 Exhibit 29: Asia - Market size and forecast 2020-2025 ($ million) Exhibit 30: Asia - Year-over-year growth 2020-2025 (%) 7.6 ROW - Market size and forecast 2020-2025 Exhibit 31: ROW - Market size and forecast 2020-2025 ($ million) Exhibit 32: ROW - Year-over-year growth 2020-2025 (%) 7.7 Key leading countries Exhibit 33: Key leading countries 7.8 Market opportunity by geography Exhibit 34: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges Exhibit 35: Impact of drivers and challenges 8.3 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 36: Vendor landscape 9.3 Landscape disruption Exhibit 37: Landscape disruption Exhibit 38: Industry risks 10 Vendor Analysis 10.1 Vendors covered Exhibit 39: Vendors covered 10.2 Market positioning of vendors Exhibit 40: Market positioning of vendors 10.3 Astellas Pharma Inc. Exhibit 41: Astellas Pharma Inc. - Overview Exhibit 42: Astellas Pharma Inc. - Product and service Exhibit 43: Astellas Pharma Inc. - Key news Exhibit 44: Astellas Pharma Inc. - Key offerings 10.4 Bayer AG Exhibit 45: Bayer AG - Overview Exhibit 46: Bayer AG - Business segments Exhibit 47: Bayer AG - Key news Exhibit 48: Bayer AG - Key offerings Exhibit 49: Bayer AG - Segment focus 10.5 Johnson and Johnson Inc. Exhibit 50: Johnson and Johnson Inc. - Overview Exhibit 51: Johnson and Johnson Inc. - Business segments Exhibit 52: Johnson and Johnson Inc. - Key news Exhibit 53: Johnson and Johnson Inc. - Key offerings Exhibit 54: Johnson and Johnson Inc. - Segment focus 10.6 Novartis AG Exhibit 55: Novartis AG - Overview Exhibit 56: Novartis AG - Business segments Exhibit 57: Novartis AG - Key news Exhibit 58: Novartis AG - Key offerings Exhibit 59: Novartis AG - Segment focus 10.7 Perrigo Co. Plc Exhibit 60: Perrigo Co. Plc - Overview Exhibit 61: Perrigo Co. Plc - Business segments Exhibit 62: Perrigo Co. Plc - Key news Exhibit 63: Perrigo Co. Plc - Key offerings Exhibit 64: Perrigo Co. Plc - Segment focus 10.8 Pfizer Inc. 10.9 Seikagaku Corp. Exhibit 69: Seikagaku Corp. - Overview Exhibit 70: Seikagaku Corp. - Business segments Exhibit 71: Seikagaku Corp. - Key offerings Exhibit 72: Seikagaku Corp. - Segment focus 10.10 Sun Pharmaceutical Industries Ltd. Exhibit 73: Sun Pharmaceutical Industries Ltd. - Overview Exhibit 74: Sun Pharmaceutical Industries Ltd. - Product and service Exhibit 75: Sun Pharmaceutical Industries Ltd. - Key news Exhibit 76: Sun Pharmaceutical Industries Ltd. - Key offerings 10.11 Teva Pharmaceutical Industries Ltd. Exhibit 77: Teva Pharmaceutical Industries Ltd. - Overview Exhibit 78: Teva Pharmaceutical Industries Ltd. - Business segments Exhibit 79: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibit 80: Teva Pharmaceutical Industries Ltd. - Segment focus 10.12 Viatris Inc. Exhibit 81: Viatris Inc. - Overview Exhibit 82: Viatris Inc. - Business segments Exhibit 83: Viatris Inc. - Key offerings Exhibit 84: Viatris Inc. - Segment focus 11 Appendix 11.1 Scope of the report 11.2 Currency conversion rates for US$ Exhibit 85: Currency conversion rates for US$ 11.3 Research methodology Exhibit 86: Research Methodology Exhibit 87: Validation techniques employed for market sizing Exhibit 88: Information sources 11.4 List of abbreviations Exhibit 89: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

100 Deals associated with Phenazopyridine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D05450	Phenazopyridine Hydrochloride	G04BX06	DB01438

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain	CN	Karen Pharmaceutical Co. Ltd.	01 Jan 2003

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Shock, Septic	Preclinical	GB	University of Western Ontario	01 Jul 2024
Urinary Incontinence	Discovery	US	Amneal Intermediate, Inc.	01 Feb 2012
Burns	Discovery	US	Amneal Intermediate, Inc.	01 Dec 2009
Dysuria	Discovery	-	Laboratórios Osório de Moraes Ltda	01 Dec 2009
Pain	Discovery	US	Amneal Intermediate, Inc.	01 Dec 2009
Urinary Tract Infections	Discovery	US	Amneal Intermediate, Inc.	01 Dec 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03755089 (Pubmed) Manual	Phase 4	Urinary Bladder, Overactive	100	phenazopyridine	(mmoroyzwrt): difference = -2.7 (95% CI, -11.3 to 10.7)	Negative	14 May 2022
				lidocaine
NCT02476448 (JET, CTgov)	Not Applicable	Ureteral Diseases	176	normal saline (Normal Saline)	tsekcuyuda(ndfxrfzshm) = jrkreryjfy muopsfipgy (qsozhdbltx, hwnvmofpcj - axojphnepw) View more	-	23 Oct 2019
				Dextrose 10% (Dextrose 10%)	tsekcuyuda(ndfxrfzshm) = myailaqxkn muopsfipgy (qsozhdbltx, oyflbctoxg - jhqajyzypc) View more
NCT02677623 (CTgov)	Phase 4	Ureteral Obstruction	140	Pyridium (A- Pyridium)	sjmtdhvadk(kynfcvlzmw) = xdxspmxjst jmfgcjpktq (vytxgkqzhv, sybwcpnbid - pddvgjlxaq) View more	-	30 May 2019
				Sodium Fluorescein (B- Sodium Fluorescein)	sjmtdhvadk(kynfcvlzmw) = jgejksccac jmfgcjpktq (vytxgkqzhv, zrneavwikv - zimqsgphio) View more
NCT03065075 (Pubmed \| Female Pelvic Med Reconstr Surg)	Phase 3	Visceral Prolapse	152	Phenazopyridine 200 mg	xipkdpsoje(kqgenotrmw) = nutiltyfjn jwgtjvzeln (kqvxdynkzu )	Negative	26 Apr 2019
				No additional phenazopyridine	xipkdpsoje(kqgenotrmw) = yanyuvcfit jwgtjvzeln (kqvxdynkzu )
NCT03065075 (EPOV, CTgov)	Phase 3	Uterine Prolapse \| Urinary Retention	152	Phenazopyridine (Phenazopyridine)	krukhliwho(ladwmystft) = igxoywsvzk gzzdwdtana (xqnmxofsxy, ngukdjrksk - oipzuuvywt) View more	-	26 Mar 2019
				Phenazopyridine (No Phenazopyridine)	krukhliwho(ladwmystft) = phcvyrslzs gzzdwdtana (xqnmxofsxy, kwjitwtjgn - gywzxdjige) View more
NCT02806713 (EPIPhANy, CTgov)	Phase 3	Urologic Diseases \| Pain, Postoperative	92	no Phenazopyridine (no Phenazopyridine)	cjrndstxae(pcmpwiyviz) = gcxwttwdyq cppkrttjzy (eedamtgzdk, gljpybxrdi - nhpzgvglbf) View more	-	05 Feb 2019
				Phenazopyridine (Phenazopyridine)	cjrndstxae(pcmpwiyviz) = axgltdfssw cppkrttjzy (eedamtgzdk, avyvyswubu - sqlhuomlfe) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis